BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.29
arrow_downward
-5.85%(-0.52) 1D
$8.35
arrow_upward
+0.72% (+0.060)todayPre-market
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$8.34
High
$8.46
Low
$8.04
Mkt. cap
2.12B
Avg. vol.
3.34M
Volume
812.00
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
Open
$8.34
High
$8.46
Low
$8.04
Mkt. cap
2.12B
Avg. vol.
3.34M
Volume
812.00
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
Yahoo Finance
·
19 hours ago
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
GuruFocus
·
19 hours ago
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00
TipRanks
·
21 hours ago
BioCryst Slides As Rival Drug Threatens Orladeyo
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com